Anixa Biosciences Announces Progress in Cancer Therapies
Key Updates:
-
Ovarian Cancer Therapy: Anixa’s CAR-T therapy, lira-cel, has reached the highest dose level in a Phase 1 trial. Four participants have exceeded one year of survival, with a maximum of approximately 28 months.
-
Breast Cancer Vaccine: The final Phase 1 data for Anixa’s breast cancer vaccine indicates all primary endpoints were met, with 74% of participants showing protocol-defined immune responses. Phase 2 preparations are currently underway.
-
Upcoming Conference: Anixa management, including Dr. Amit Kumar, will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, highlighting recent advancements.
Details of the Presentation:
- Date and Time: Begins at 7:00 AM ET on September 11, 2026.
- Webcast Link
About Anixa Biosciences:
- Anixa is a clinical-stage biotechnology firm specializing in cancer treatment and prevention. Their innovative CAR-T technology is developed with Moffitt Cancer Center, while their vaccine offerings are in collaboration with Cleveland Clinic.
Contact Information:
- Mike Catelani
- President, COO & CFO
- 408-708-9808
Note: Forward-looking statements are made in accordance with securities legislation, reflecting expectations for future results.
For more information, visit Anixa’s website.
